Proton therapy has been approved by the FDA as a form of cancer treatment for over 30 years. But does it provide any added benefit over photon therapy? Penn Center for Cancer Care Innovation (PC3I) Director Justin Bekelman, MD, discusses this ongoing debate and how to resolve it with Managed Healthcare Executive. The article elevates the nuanced, ongoing conversations around photon versus proton therapy for cancer treatment, specifically highlighting PC3I’s RadComp Study. The RadComp study, short for Radiotherapy Comparative Effectiveness, is currently comparing these two types of radiation therapies for the treatment of breast cancer.
Both photons and protons break down DNA within cancer cells, thus preventing those cells from replicating. Neither photon nor proton therapy is experimental. Both are on the cutting-edge of cancer therapy.
“What remains undefined is whether [proton beam therapy] is any better than what we currently use…. It is a proven treatment, but is it proven as better than what we usually do for the prevalent cancers? The answer is not yet,” Bekelman shared.
Bekelman also highlights an ongoing barrier to enrollment in clinical trials designed to answer these questions, saying, “There remains a gap in engagement across manufacturers, providers, insurers, and funders on how to pay for proton therapy treatments as part of large definitive randomized trials of this technology.”
Continue reading the full article at Managed Healthcare Executive.
Reflecting on 50 years of the National Cancer Act, PC3I Faculty Ravi Parikh shares his thoughts with AARP on new cancer treatments and improvements in managing treatment side effects.
Dr. Christine Edmonds and PC3I Faculty Dr. Lola Fayanju share several ways in which Black women experience socioeconomic barriers and systemic biases that impact breast cancer treatment and survival.
Researchers from the Population-based Research to Optimize the Screening Process (PROSPR) Consortium are working to eliminate disparities in uptake of lung cancer screening.